29 / 50
The benefit of the Addition of NK
1
Receptor Antagonists in patients receiving
carboplatin:
- Results of Phase III Trials -
Overall (0–120 hours)
No emesis rate
NK
1
RA + 5-HT
3
RA + DEX
5-HT
3
RA + DEX
Absolute
difference
Gralla (N = 192)
84%
70%
14%
Overall (0–120 hours)
Complete response
NK
1
RA + 5-HT
3
RA + DEX
5-HT
3
RA + DEX
Absolute
difference
Tanioka (N = 91) *
62%
52%
10%
Ito (N = 134)
80%
67%
14%
Yahata (N = 324) *
62%
47%
15%
Hesketh (N = 401)
80%
65%
15%
Jordan K.
Ann Oncol.
2015; 26:1081-1090. Gralla R.
J Clin Oncol.
2010;28: Abst 9057. Tanoika M.
Br J Cancer.
2013;109:859-865. Ito Y.
Lung Cancer
. 2014;84:259-264.
Yahata H.
Ann Oncol.
2014;25: Abst 1481PD. Hesketh PJ, et al.
J Clin Oncol.
2016 34:381-386.
*GYN only